All Outputs (2)

Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK (2023)
Journal Article
Walsh, T. S., Aitken, L. M., McKenzie, C. A., Boyd, J., Macdonald, A., Giddings, A., …Page, V. J. (2023). Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical a

Introduction: Almost all patients receiving mechanical ventilation (MV) in intensive care units (ICUs) require analgesia and sedation. The most widely used sedative drug is propofol, but there is uncertainty whether alpha2-agonists are superior. The... Read More about Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK.

Correction: Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation Correction: After Resuscitation-2 (RADAR-2) randomised clinical trial (2023)
Journal Article
Silversides, J. A., McMullan, R., Emerson, L. M., Bradbury, I., Bannard-Smith, J., Szakmany, T., …McAuley, D. F. (2023). Correction: Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the R